CRISPR Therapeutics adds Simeon George, Ali Behbahani and Kurt von Emster to Board after closing Series A and Series B financing totaling $89m

– SWITZERLAND, Basel / USA, MA – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced the closing of a Series A and Series B financing totaling USD 89 million, including USD 35 million of new funding in the Series A and USD 29 million in the Series B.…

Kura Oncology appoints Faheem Hasnain to the Board of Directors

– USA, CA – Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the appointment of Faheem Hasnain to the Company’s board of directors.…